US offering investment to boost COVID-19 vaccine capacity


WASHINGTON (AP) — The Biden administration is making billions of dollars available to drugmakers to scale up domestic production of COVID-19 vaccines in the hopes of building capacity to produce an additional 1 billion shots per year to share with the world.

Under the new initiative, the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority is soliciting pharmaceutical companies that have demonstrated the ability to make the more-effective mRNA vaccines to bid for government investment in scaling up their manufacturing abilities. Drugmakers Pfizer and Moderna produce the two U.S.-approved mRNA shots.

The Biden administration believes the boosted capacity of COVID-19 shots will help ease a global shortage of doses, particularly in lower- and middle-income nations, stopping preventable death and limiting the development of potentially new, more dangerous variants of the virus.

“The goal of this program is to expand existing capacity by an additional billion doses per year, with production starting by the second half of 2022,” White House COVID-19 coordinator Jeff Zients said.

The initiative comes as the Biden White House has faced growing pressure at home and abroad over inequity in the global vaccine supply — as the U.S. moves toward approving booster shots for all adults while vulnerable people in poorer nations wait for their first dose of protection.

There are no firm agreements yet with Moderna or Pfizer to take up the U.S. on the investment, but the Biden administration hopes that the enhanced manufacturing capacity, through support for the company’s facilities, equipment, staff or training, will be available by mid-2022 to allow more COVID-19 doses to be shared overseas as well as to prepare for the next public health emergency.

“Investments being considered may involve costs associated with infrastructure (facilities/equipment), bolstering trained staff and long-term sustainment (‘readiness’) for COVID-19 vaccine, or variants of concern, and emerging infectious disease/pandemic response at no less than 100 million doses per month over and above current U.S.-based capacity,” the solicitation says.

Robbie Silverman, senior advocacy manager at Oxfam America, welcomed Biden’s plan to invest into vaccine manufacturing capacity but said it was nowhere near sufficient.

“What the world really needs is distributed regional manufacturing capacity of vaccines, and it sounds like this investment is focused on building U.S. capacity,” he said. “We desperately need the companies who have a monopoly over the COVID vaccines to transfer their technology, and we need the U.S. government to use its leverage.”

Silverman estimated that without companies transferring their knowledge of how to make COVID-19 vaccines, it would take manufacturers elsewhere double the time needed to start making doses, noting that billions of vaccines against other diseases are routinely made in developing countries.

Silverman said that while the U.S. should have negotiated more provisions about vaccine equity when it was securing its own supply, it was not too late to act. He said the U.S. should be acting to support the proposed waiver that was drafted by India and South Africa at the World Trade Organization, calling for patents on COVID-19 vaccines and treatments to be suspended. And he said the U.S. could invoke the Defense Production Act to target critical ingredients for COVID-19 shots.

“The U.S. government has lots of tools at its disposal to push pharmaceutical companies,” he said, noting that it had invested billions of dollars into creating Moderna’s COVID-19 vaccine. “The U.S. needs to make sure these companies, which they funded, are prioritizing public health rather than profits.”

Ava Alkon, a senior policy and research officer at Doctors Without Borders, said that the billion doses that might be produced with the U.S. investment were still far from the figure needed to immunize the world. The World Health Organization has estimated that 11 billion doses are needed.

Alkon said that since any manufacturers newly drafted into making COVID-19 doses would not be able to produce any supplies for several months, a more immediate solution is needed. “We believe that the U.S. can distribute many more doses than it already has on an ongoing basis,” she said, calling for the U.S. to be more transparent about how many extra doses it has. She said some estimates suggest the U.S. could have at least 500 million surplus vaccines by the end of the year.

The New York Times first reported on the new initiative.


AP writer Maria Cheng in London contributed.

FILE – A dose of a Pfizer COVID-19 vaccine is prepared at Lurie Children’s hospital, Nov. 5, 2021, in Chicago. The Biden administration is making billions of dollars available to drugmakers to scale up domestic production of COVID-19 vaccines in the hopes of building capacity to produce an additional 1 billion shots per year to share globally. (AP Photo/Nam Y. Huh, File)

Reset password

Enter your email address and we will send you a link to change your password.

Get started with your account

to save your favourite homes and more

Sign up with email

Get started with your account

to save your favourite homes and more

By clicking the «SIGN UP» button you agree to the Terms of Use and Privacy Policy
Powered by Estatik
error: Content is protected !!